C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/12 (2006.01) A61K 31/7088 (2006.01) A61K 38/08 (2006.01) A61K 38/10 (2006.01) A61K 38/17 (2006.01) A61K 39/395 (2006.01) A61K 48/00 (2006.01) A61P 35/00 (2006.01) C07K 14/47 (2006.01) C07K 16/18 (2006.01) C12N 15/11 (2006.01) C12N 15/13 (2006.01) C12Q 1/68 (2006.01) G01N 33/574 (2006.01) C07K 14/15 (2006.01) C07K 14/705 (2006.01)
Patent
CA 2745849
The present invention relates to polynucleotide and polypeptide sequences of a novel human endogenous retroviral ERV3 variant which is differentially expressed in ovarian cancer cells when compared to normal cells. The present invention more particularly relates to the use of these polynucleotide and polypeptide in the diagnosis, prognosis or treatment of cancer and in the detection of cancer cells.
La présente invention concerne des séquences polynucléotidique et polypeptidique dun nouveau variant rétroviral endogène humain dERV3 qui est exprimé de manière différentielle dans des cellules de cancer des ovaires par rapport à des cellules normales. La présente invention concerne plus particulièrement lutilisation de ces polynucléotide et polypeptide dans le diagnostic, le pronostic ou le traitement du cancer et dans la détection de cellules cancéreuses.
Filion Mario
Moraitis Anna
Tremblay Gilles Bernard
Alethia Biotherapeutics Inc.
Forget Janique
LandOfFree
Novel human endogenous retorviral erv3 variant and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Novel human endogenous retorviral erv3 variant and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel human endogenous retorviral erv3 variant and uses... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1491021